Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureShahrokh Khoshsirat, Negar Naderi, Forouzan Karimi, Leila Mohaghegh Shalmani, Safura Pournajaf
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought
10.1097/00129492-200501000-00016 · 2005
Epidemiology of vestibular schwannomas–prospective 40-year data from an unselected national cohort
10.2147/clep.s218670 · 2019
Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation
10.1136/jmg.40.11.802 · 2003
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane
10.1083/jcb.200503165 · 2005
NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications
10.1097/mao.0b013e318298ac79 · 2013
Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma
10.1093/hmg/3.2.347 · 1994
NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study
10.1136/jmg-2024-110065 · 2024
A matched cohort comparison of clinical outcomes following microsurgical resection or stereotactic radiosurgery for patients with small- and medium-sized vestibular schwannomas
10.3171/2015.12.jns151857 · 2016
Recurrences and progression following microsurgery of vestibular schwannoma
10.3389/fsurg.2023.1216093 · 2023
Wait and scan” management of patients with vestibular schwannoma and the relevance of non-contrast MRI in the follow-up
10.1016/j.joto.2017.08.002 · 2017
EANO guideline on the diagnosis and treatment of vestibular schwannoma
10.1093/neuonc/noz153 · 2020
Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions—A Scoping Review
10.3390/cimb48030292 · 2026
Vestibular schwannomas
10.1056/nejmra2020394 · 2021
The molecular biology and novel treatments of vestibular schwannomas: a review
10.3171/2011.6.jns11131 · 2011
[Pathogenesis and molecular pathology of vestibular schwannoma]
10.1007/s00106-016-0201-3 · 2017
Schwannomas and Their Pathogenesis
10.1111/bpa.12125 · 2014
Histomorphological Spectrum and Diagnostic Utility of S100, SOX10, CD34, Calretinin, and Ki67 in the Evaluation of Schwannomas: A Retrospective Study of 26 Cases in a Tertiary Health Institute, Zaria-Nigeria
10.4103/jwas.jwas_177_24 · 2025
Nerve origin of vestibular schwannoma: a prospective study
10.1017/s0022215107001028 · 2007
The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level
10.1097/01.mao.0000180484.24242.54 · 2006
Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas
10.3390/cancers17030393 · 2025
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus
10.1016/j.cell.2010.01.029 · 2010
Schwann cells in the inner ear: development, disease, and regeneration
10.3389/fncel.2025.1662274 · 2025
The comparable tumour microenvironment in sporadic and NF2-related schwannomatosis vestibular schwannoma
10.1093/braincomms/fcad197 · 2023
Interactions among Merlin, Arkadia, and SKOR2 mediate NF2-associated human Schwann cell proliferation
10.1186/s13287-025-04281-x · 2025
Hearing loss and vestibular schwannoma: new insights into Schwann cells implication
10.1038/s41419-023-06141-z · 2023
Immune profiling of human vestibular schwannoma secretions identifies TNF-α and TWEAK as cytokines with synergistic potential to impair hearing
10.1186/s12974-025-03364-z · 2025
Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth
10.1016/j.molonc.2015.03.009 · 2015
Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells
2016
SMARCB1-related schwannomatosis and other SMARCB1-associated phenotypes: clinical spectrum and molecular pathogenesis
10.1007/s10689-025-00486-4 · 2025
Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis
10.3390/ijms22115850 · 2021
Angiogenesis in vestibular schwannomas: expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1
10.1002/lary.20834 · 2010
The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence
10.1159/000346238 · 2013
Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue
10.3892/mmr.2015.3415 · 2015
Potential molecular biomarkers of vestibular schwannoma growth: progress and prospects
2021
Single-cell sequencing reveals the cell map and transcriptional network of sporadic vestibular schwannoma
10.3389/fnmol.2022.984529 · 2022
Immunohistochemical Profiles of Matrix Metalloproteinases and Vascular Endothelial Growth Factor Overexpression in the Antoni B Area of Vestibular Schwannomas
10.1016/j.wneu.2020.07.208 · 2020
Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells
10.4161/15384047.2014.972765 · 2015
Matrix metalloproteinase 9: An emerging biomarker for classification of adherent vestibular schwannoma
2024
Cystic vestibular schwannomas: a possible role of matrix metalloproteinase–2 in cyst development and unfavorable surgical outcome
10.3171/jns.2007.106.5.866 · 2007
Identifying Tumor Microenvironment Biomarkers in Adherent and Cystic Vestibular Schwannomas
10.1097/mao.0000000000004073 · 2024
Advancements in preclinical models for NF2-related schwannomatosis research
10.3390/cancers18020224 · doi-reference
Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of β-catenin
10.1038/s41401-022-00908-4 · doi-reference
NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation
10.1038/onc.2010.20 · doi-reference
Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation
10.1038/cdd.2016.54 · doi-reference
Wnt/β-catenin signaling: components, mechanisms, and diseases
10.1016/j.devcel.2009.06.016 · doi-reference
Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/β-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways
10.1593/neo.111060 · doi-reference
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
10.1038/s41392-025-02142-w · doi-reference
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
10.1038/s43018-023-00577-0 · doi-reference
10.1126/science.adf4478
10.1126/science.adf4478 · doi-reference
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
10.1101/gad.2000111 · doi-reference
The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancer
10.1038/s12276-025-01551-9 · doi-reference
YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis
10.1158/0008-5472.can-15-1144 · doi-reference
Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma
10.1016/j.wneu.2018.06.010 · doi-reference
Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling
10.1172/jci.insight.141514 · doi-reference
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
10.18632/oncotarget.659 · doi-reference
Merlin inhibits growth hormone-regulated Raf–ERKs pathways by binding to Grb2 protein
10.1016/j.bbrc.2005.12.122 · doi-reference
PAK kinase regulates Rac GTPase and is a potential target in human schwannomas
10.1016/j.expneurol.2009.04.019 · doi-reference
The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling
10.1038/s41388-019-0883-6 · doi-reference
Inhibition of MEK pathway in vestibular schwannoma cell culture
10.1002/lary.23472 · doi-reference
RAS proteins and their regulators in human disease
10.1016/j.cell.2017.06.009 · doi-reference
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac
10.1158/0008-5472.can-06-1608 · doi-reference
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
10.1016/j.bbamcr.2006.10.001 · doi-reference
Merlin, a multi-suppressor from cell membrane to the nucleus
10.1016/j.febslet.2012.03.016 · doi-reference
Effect of AR42 in Primary Vestibular Schwannoma Cells and a Xenograft Model of Vestibular Schwannoma
10.1097/mao.0000000000003556 · doi-reference
Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells
10.3390/ijms27062636 · doi-reference
CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells
10.18632/oncotarget.28254 · doi-reference
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
10.1007/s11060-014-1710-0 · doi-reference
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas
10.1093/neuonc/not150 · doi-reference
Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells
10.1016/j.ejca.2009.03.013 · doi-reference
Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis
10.1038/s41388-024-02958-w · doi-reference
Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells
10.1158/1535-7163.mct-23-0135 · doi-reference
Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis
10.3390/cancers12010177 · doi-reference
Merlin tumor suppressor function is regulated by PIP2-mediated dimerization
10.1371/journal.pone.0281876 · doi-reference
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas
10.1002/lary.22392 · doi-reference
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L
10.1073/pnas.0405971102 · doi-reference
Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types
10.1158/1541-7786.mcr-11-0425-t · doi-reference
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth
10.1128/mcb.01581-08 · doi-reference
The mTOR Pathway in Hearing Disorders: Mechanistic Links to Aging, Regeneration, and Neurodegeneration
10.1007/s12035-025-05653-3 · doi-reference
The mTOR pathway in Gliomas: From molecular insights to targeted therapies
10.1016/j.biopha.2025.118237 · doi-reference
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
10.1073/pnas.1016140108 · doi-reference